Welcome to our dedicated page for Aptargroup news (Ticker: ATR), a resource for investors and traders seeking the latest updates and insights on Aptargroup stock.
AptarGroup, Inc. (NYSE: ATR) generates news across drug delivery, digital health and consumer dispensing technologies. As a global company serving pharmaceutical, beauty, food, beverage, personal care and home care markets, its announcements often highlight new delivery systems, clinical collaborations, acquisitions and financial updates that are relevant to investors and industry observers.
Recent news has featured Aptar Pharma’s nasal and ophthalmic platforms, such as LuerVax and Spray Divider being used in a Phase II clinical trial of an intranasal COVID-19 vaccine candidate, and Bidose liquid nasal spray systems delivering an FDA-approved treatment for paroxysmal supraventricular tachycardia. The company also reports on developments in eye care, including its Beat the Blink technology and preservative-free multidose dispensers, as well as broader portfolios of ophthalmic solutions.
Aptar’s Digital Health division appears frequently in updates related to connected health tools and data-driven care. Examples include the integration of the Migraine Buddy app with biometric data from wearable devices and FDA 510(k) clearance for HeroTracker Sense, a connected add-on for metered-dose inhalers within a respiratory disease management platform.
Investors following ATR news will also find earnings releases, segment performance commentary, conference participation announcements and information on capital markets activity, such as senior notes offerings. This news page brings together these items so readers can review Aptar’s latest product milestones, partnerships, digital health initiatives and financial communications in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
AptarGroup, Inc. (NYSE: ATR) has announced a quarterly cash dividend of $0.38 per share, with a payment date set for May 25, 2023 for shareholders on record as of May 4, 2023. The company, based in Crystal Lake, Illinois, specializes in drug delivery and consumer product dispensing solutions across various markets, including pharmaceuticals and personal care. Additionally, Aptar will conduct a conference call on April 28, 2023, at 8:00 a.m. CT to discuss its Q1 2023 results. Interested parties can access the live webcast through the company's Investors page.